Celadon Pharmaceuticals Plc

Canaccord Genuity acted as Nomad, Financial Adviser and Sole Broker to Celadon Pharmaceuticals Plc on its admission to trading on the London Stock Exchange

Canaccord Genuity’s Corporate Broking team is pleased to announce it has acted as Nomad, Sole Bookrunner and Sole Broker to Celadon Pharmaceuticals Plc (AIM:CEL) (“Celadon”), on its admission to trading on AIM, a market operated by the London Stock Exchange plc, alongside an accompanying £8.5 million equity fundraise. Celadon had a market capitalisation on Admission of £97.4 million.

Celadon Pharmaceuticals Plc, is a UK based pharmaceutical company specialising in the researching, growing and supply of medicinal cannabis.

Celadon is one of the first pharmaceutical companies in the UK to receive a Home Office licence, following approval from the MHRA to apply for the licence, to grow high tetrahydrocannabinol ("THC") cannabis, for the purpose of producing test batches of cannabis oil to support its application to the MHRA for registration as a manufacturer of medicinal product APIs. Celadon’s goal is to become the provider and partner of choice for pharmaceutical cannabinoid-based medicines in the highly regulated UK market and is initially focusing on the chronic pain market. Celadon has a 100,000 square foot facility located in the Midlands, UK, that comprises a laboratory designed to meet UK-GMP standards, with capacity for a large indoor hydroponic growing facility in accordance with GACP guidelines.